Trial Profile
An Observational Safety Evaluation of Patients Treated With the NEVO Sirolimus-eluting Coronary Stent.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms NEVO-II
- Sponsors Cordis Corporation
- 24 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 20 Jul 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Nov 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.